Previous 10 | Next 10 |
home / stock / hbp:cc / hbp:cc news
(TheNewswire) Toronto, Ontario – TheNewswire – August 30, 2022 – Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique therapies in the field of ...
(TheNewswire) Toronto, Ontario – TheNewswire – August 9, 2022 – Helix BioPharma Corp . (TSX:HBP) (OTC:HBPCF) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company that is developing unique th...
VANCOUVER, BC / ACCESSWIRE / April 22, 2022 / Mr. Jerzy Wilczewski announces the acquisition of 7,700,000 common shares (" Common Shares ") in the capital of Helix Biopharma Corp. (" Helix " or the " Company ") (TSX: HBP ) at a price of $0.26 per Common Share by way of non-brokered privat...
RICHMOND HILL, ON / ACCESSWIRE / April 21, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announces that ...
RICHMOND HILL, ON / ACCESSWIRE / April 18, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platformDOS47, is pleased to announce...
RICHMOND, ON / ACCESSWIRE / April 13, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, is pleased to announce tha...
RICHMOND HILL, ON / ACCESSWIRE / April 7, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the re...
RICHMOND HILL, ON / ACCESSWIRE / March 22, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced that Fr...
RICHMOND, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP), (" Helix " or the " Company "), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced fisc...
RICHMOND HILL, ON / ACCESSWIRE / March 16, 2022 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company") today announces, with great sadness, the sudden passing of its Interim Chief Executive Officer and Chairman of the Board of Directors (the "Board"), Prof. Dr. S Slawomir Majewski. Dr...
News, Short Squeeze, Breakout and More Instantly...
Helix BioPharma Corp. Company Name:
HBP:CC Stock Symbol:
TSXC Market:
Crown Capital Partners Inc. (CRWN:CA) is expected to report for Q1 2024 Aberdeen International Inc. (AAB:CA) is expected to report for Q1 2025 Haivision Systems Inc. (HAI:CA) is expected to report for Q2 2024 Peyto Exploration & Development Corp. (PEY:CA) is expected to report $0....
Batero Gold Corp. (BAT:CA) is expected to report for Q2 2024 Barrick Gold Corporation (ABX:CA) is expected to report $0.22 for Q1 2024 Exco Technologies Limited (XTC:CA) is expected to report $0.17 for Q2 2024 Amerigo Resources Ltd. (ARG:CA) is expected to report for Q1 2024 Parkl...
Wall Financial Corporation (WFC:CA) is expected to report for quarter end 2024-01-31 Helix BioPharma Corp. (HBP:CA) is expected to report for Q2 2024 Choice Properties Real Estate Investment Trust (CHP.UN:CA) is expected to report $0.26 for Q1 2024 Celestica Inc. Subordinate Voting Sh...